Glenmede Trust CO Na Bei Gene, Ltd. Transaction History

Glenmede Trust CO Na

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $25,008 - $35,776	-113 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$189.18 - $286.44 $8,134 - $12,316	43 Added 61.43%	113 $32,000
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $5,079 - $8,011	41 Added 141.38%	70 $13,000
Q4 2019 Feb 12, 2020	BUY	$115.78 - $208.34 $231 - $416	2 Added 7.41%	29 $4,000
Q3 2019 Nov 14, 2019	BUY	$120.61 - $148.29 $1,929 - $2,372	16 Added 145.45%	27 $3,000
Q2 2019 Aug 13, 2019	BUY	$113.99 - $146.86 $1,253 - $1,615	11 New	11 $1,000

249

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.